After skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the United States. In fact, one in eight men will be diagnosed with prostate cancer during their lifetime, ...

A multicenter clinical study in Austria has shown that a new, highly precise ultrasound approach can successfully target and ...

Former President Joe Biden has reportedly completed radiation and hormone therapy for aggressive prostate cancer at Penn ...

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Curium has entered a partnership with the Czech company ÚJV Řež, a leading expert in the development and production of ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a medicine that is used to treat prostate cancer in adults. Pluvicto may be used to treat PSMA-positive prostate cancer that has spread to other ...

The Nuclear Medicine Department at Ridley-Tree Cancer Center (now part of Sutter Health) has announced greater capabilities to treat prostate cancer using the injectable radioligand therapy, Pluvicto ...

Dr. Kurt N. Ransohoff, President, Sutter Health Greater Central Coast, moderated the multidisciplinary panel of six ...

Oncologists and urologists identified several barriers to treatment intensification for metastatic castration-sensitive ...

Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.